WP Thyroid — Class I drug recall D-1614-2020
Terminated recall by RLC Labs Inc., reported 2020-09-23, distributed nationwide. Subpotent Drug: FDA analysis found product to be subpotent
| Recall number | D-1614-2020 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | RLC Labs Inc., Phoenix, AZ, United States |
| Recall initiated | 2020-08-25 |
| Classified | 2020-09-24 |
| Reported by FDA | 2020-09-23 |
| Terminated | 2023-11-08 |
| Distributed | Nationwide (US) |
| Reason classes | potency |
| NDC | 64727-5550-01, 64727-5550-04, 64727-5550-06 |
| Lot numbers | 119142 |
| Expiration dates | 2022-01 |
Product
WP Thyroid, Westhroid Pure, 1/2 Grain (32.5 mg) Thyroid USP [Liothyronine (T3) 4.5 mcg, Levothyroxine (T4) 19 mcg], packaged in a) 30-count bottles (NDC 64727-5550-4), b) 90-count bottles (NDC 64727-5550-6), c) 100-count bottles (NDC 64727-5550-1), Rx only, Manufactured by: RLC Labs Phoenix, AZ 85024
Reason for recall
Subpotent Drug: FDA analysis found product to be subpotent
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1614-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.